H Uri Saragovi - Publications

McGill University, Montreal, QC, Canada 
Pharmacology, Neuroscience Biology, Cell Biology

104 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Josephy-Hernandez S, Pirvulescu I, Maira M, Aboulkassim T, Wong TP, McKinney RA, Saragovi HU. Pharmacological interrogation of TrkA-mediated mechanisms in hippocampal-dependent memory consolidation. Plos One. 14: e0218036. PMID 31233568 DOI: 10.1371/journal.pone.0218036  0.4
2019 Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy. Cell Chemical Biology. PMID 31105061 DOI: 10.1016/j.chembiol.2019.03.018  0.4
2018 Barcelona PF, Galan A, Nedev H, Jian Y, Sarunic MV, Saragovi HU. The route of administration influences the therapeutic index of an anti-proNGF neutralizing mAb for experimental treatment of Diabetic Retinopathy. Plos One. 13: e0199079. PMID 29927948 DOI: 10.1371/journal.pone.0199079  0.32
2017 Galán A, Jmaeff S, Barcelona PF, Brahimi F, Sarunic MV, Saragovi HU. In retinitis pigmentosa TrkC.T1-dependent vectorial Erk activity upregulates glial TNF-α, causing selective neuronal death. Cell Death & Disease. 8: 3222. PMID 29242588 DOI: 10.1038/s41419-017-0074-8  0.32
2017 Galan A, Barcelona PF, Nedev H, Sarunic MV, Jian Y, Saragovi HU. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy. Investigative Ophthalmology & Visual Science. 58: 2852-2862. PMID 28570737 DOI: 10.1167/iovs.16-20988  0.32
2016 Brahimi F, Maira M, Barcelona PF, Galan A, Aboulkassim T, Teske K, Rogers ML, Bertram L, Wang J, Yousefi M, Rush R, Fabian M, Cashman N, Saragovi HU. The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS. Plos One. 11: e0162307. PMID 27695040 DOI: 10.1371/journal.pone.0162307  0.4
2016 Barcelona PF, Sitaras N, Galan A, Esquiva G, Jmaeff S, Jian Y, Sarunic MV, Cuenca N, Sapieha P, Saragovi HU. p75NTR and Its Ligand ProNGF Activate Paracrine Mechanisms Etiological to the Vascular, Inflammatory, and Neurodegenerative Pathologies of Diabetic Retinopathy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 8826-41. PMID 27559166 DOI: 10.1523/JNEUROSCI.4278-15.2016  1
2015 Tong W, Maira M, Gagnon M, Saragovi HU. Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. Plos One. 10: e0134255. PMID 26252487 DOI: 10.1371/journal.pone.0134255  1
2015 Barcelona PF, Saragovi HU. A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo. Molecular and Cellular Biology. 35: 3396-408. PMID 26217017 DOI: 10.1128/MCB.00544-15  1
2015 Goupil E, Fillion D, Clément S, Luo X, Devost D, Sleno R, Pétrin D, Saragovi HU, Thorin É, Laporte SA, Hébert TE. Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells. The Journal of Biological Chemistry. 290: 3137-48. PMID 25512374 DOI: 10.1074/jbc.M114.631119  1
2014 Galan A, Dergham P, Escoll P, de-la-Hera A, D'Onofrio PM, Magharious MM, Koeberle PD, Frade JM, Saragovi HU. Neuronal injury external to the retina rapidly activates retinal glia, followed by elevation of markers for cell cycle re-entry and death in retinal ganglion cells. Plos One. 9: e101349. PMID 24983470 DOI: 10.1371/journal.pone.0101349  1
2014 Brahimi F, Ko E, Malakhov A, Burgess K, Saragovi HU. Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors Plos One. 9. PMID 24603864 DOI: 10.1371/journal.pone.0089617  1
2013 Mysona BA, Al-Gayyar MM, Matragoon S, Abdelsaid MA, El-Azab MF, Saragovi HU, El-Remessy AB. Modulation of p75(NTR) prevents diabetes- and proNGF-induced retinal inflammation and blood-retina barrier breakdown in mice and rats. Diabetologia. 56: 2329-39. PMID 23918145 DOI: 10.1007/s00125-013-2998-6  1
2013 Garcia AG, Nedev H, Bijian K, Su J, Alaoui-Jamali MA, Saragovi HU. Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs. Oncogene. 32: 2527-33. PMID 22797066 DOI: 10.1038/onc.2012.283  1
2013 Ivanisevic L, Saragovi HU. Neurotrophins Handbook of Biologically Active Peptides. 1639-1646. DOI: 10.1016/B978-0-12-385095-9.00224-4  1
2012 Ettinger K, Lecht S, Arien-Zakay H, Cohen G, Aga-Mizrachi S, Yanay N, Saragovi HU, Nedev H, Marcinkiewicz C, Nevo Y, Lazarovici P. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cellular Signalling. 24: 2378-88. PMID 22960610 DOI: 10.1016/j.cellsig.2012.08.008  1
2012 Tong W, Sprules T, Gehring K, Saragovi HU. Rational design of peptide ligands against a glycolipid by NMR studies. Methods in Molecular Biology (Clifton, N.J.). 928: 39-52. PMID 22956132 DOI: 10.1007/978-1-62703-008-3_4  1
2011 Jain P, Li R, Lama T, Saragovi HU, Cumberlidge G, Meerovitch K. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Experimental Eye Research. 93: 503-12. PMID 21726552 DOI: 10.1016/j.exer.2011.06.014  1
2011 Aboulkassim T, Tong XK, Tse YC, Wong TP, Woo SB, Neet KE, Brahimi F, Hamel E, Saragovi HU. Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory. Molecular Pharmacology. 80: 498-508. PMID 21616921 DOI: 10.1124/mol.111.071332  1
2011 Bai Y, Ge J, Saragovi HU, Zhuo Y. The role of neurotrophins and mimetics in the treatment of ocular diseases Drugs of the Future. 36: 123-131. DOI: 10.1358/dof.2011.036.02.1533653  1
2010 Sarunic MV, Yazdanpanah A, Gibson E, Xu J, Bai Y, Lee S, Saragovi HU, Beg MF. Longitudinal study of retinal degeneration in a rat using spectral domain optical coherence tomography. Optics Express. 18: 23435-41. PMID 21164686 DOI: 10.1364/OE.18.023435  1
2010 Bai Y, Dergham P, Nedev H, Xu J, Galan A, Rivera JC, ZhiHua S, Mehta HM, Woo SB, Sarunic MV, Neet KE, Saragovi HU. Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. The Journal of Biological Chemistry. 285: 39392-400. PMID 20943663 DOI: 10.1074/jbc.M110.147801  1
2010 Brahimi F, Liu J, Malakhov A, Chowdhury S, Purisima EO, Ivanisevic L, Caron A, Burgess K, Saragovi HU. A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist. Biochimica Et Biophysica Acta. 1800: 1018-26. PMID 20600627 DOI: 10.1016/j.bbagen.2010.06.007  1
2010 Liu J, Brahimi F, Saragovi HU, Burgess K. Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists. Journal of Medicinal Chemistry. 53: 5044-8. PMID 20540510 DOI: 10.1021/jm100148d  1
2010 Bai Y, Xu J, Brahimi F, Zhuo Y, Sarunic MV, Saragovi HU. An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Investigative Ophthalmology & Visual Science. 51: 4722-31. PMID 20357199 DOI: 10.1167/iovs.09-5032  0.32
2010 Tong W, Gagnon M, Sprules T, Gilbert M, Chowdhury S, Meerovitch K, Hansford K, Purisima EO, Blankenship JW, Cheung NK, Gehring K, Lubell WD, Saragovi HU. Small-molecule ligands of GD2 ganglioside, designed from NMR studies, exhibit induced-fit binding and bioactivity. Chemistry & Biology. 17: 183-94. PMID 20189108 DOI: 10.1016/j.chembiol.2010.01.012  1
2010 Guillemard V, Ivanisevic L, Garcia AG, Scholten V, Lazo OM, Bronfman FC, Saragovi HU. An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors. Developmental Neurobiology. 70: 150-64. PMID 19953569 DOI: 10.1002/dneu.20776  1
2010 Bassili M, Birman E, Schor NF, Saragovi HU. Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemotherapy and Pharmacology. 65: 1047-56. PMID 19701634 DOI: 10.1007/s00280-009-1110-x  1
2009 Saragovi HU, Hamel E, Di Polo A. A neurotrophic rationale for the therapy of neurodegenerative disorders. Current Alzheimer Research. 6: 419-23. PMID 19874265 DOI: 10.2174/156720509789207912  1
2009 Chen D, Brahimi F, Angell Y, Li YC, Moscowicz J, Saragovi HU, Burgess K. Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. Acs Chemical Biology. 4: 769-81. PMID 19735123 DOI: 10.1021/cb9001415  1
2009 Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU. A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides. 30: 1833-9. PMID 19647025 DOI: 10.1016/j.peptides.2009.07.015  1
2009 Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F, Hardy P, Joyal JS, Nedev H, Duhamel F, ... ... Saragovi HU, et al. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 297: R1009-18. PMID 19641130 DOI: 10.1152/ajpregu.90766.2008  1
2009 Nedev H, Saragovi HU. Synthesis of biotinyl-TN14003, anti-HIV peptide amide. Advances in Experimental Medicine and Biology. 611: 155-6. PMID 19400137 DOI: 10.1007/978-0-387-73657-0_70  1
2009 Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A. Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Molecular and Cellular Neurosciences. 40: 410-20. PMID 19146958 DOI: 10.1016/j.mcn.2008.12.005  1
2008 Kojic LD, Wiseman SM, Ghaidi F, Joshi B, Nedev H, Saragovi HU, Nabi IR. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. Plos One. 3: e3597. PMID 18974847 DOI: 10.1371/journal.pone.0003597  1
2008 Zhuo YH, Wei YT, Bai YJ, Duan S, Lin MK, Saragovi HU, Ge J. Pro370Leu MYOC gene mutation in a large Chinese family with juvenile-onset open angle glaucoma: correlation between genotype and phenotype. Molecular Vision. 14: 1533-9. PMID 18728751  1
2008 Shi Z, Rudzinski M, Meerovitch K, Lebrun-Julien F, Birman E, Di Polo A, Saragovi HU. Alpha2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma. The Journal of Biological Chemistry. 283: 29156-65. PMID 18701465 DOI: 10.1074/jbc.M802365200  1
2008 Angell Y, Chen D, Brahimi F, Saragovi HU, Burgess K. A combinatorial method for solution-phase synthesis of labeled bivalent beta-turn mimics. Journal of the American Chemical Society. 130: 556-65. PMID 18088119 DOI: 10.1021/ja074717z  1
2007 Moffett S, Mélançon D, DeCrescenzo G, St-Pierre C, Deschénes F, Saragovi HU, Gold P, Cuello AC. Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use. Hybridoma (2005). 26: 363-72. PMID 18158780 DOI: 10.1089/hyb.2007.0522  1
2007 Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Developmental Neurobiology. 67: 884-94. PMID 17506493 DOI: 10.1002/dneu.20360  1
2007 Ivanisevic L, Zheng W, Woo SB, Neet KE, Saragovi HU. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand. The Journal of Biological Chemistry. 282: 16754-63. PMID 17439940 DOI: 10.1074/jbc.M701996200  1
2006 Peleshok J, Saragovi HU. Functional mimetics of neurotrophins and their receptors. Biochemical Society Transactions. 34: 612-7. PMID 16856874 DOI: 10.1042/BST0340612  1
2006 Esteban PF, Yoon HY, Becker J, Dorsey SG, Caprari P, Palko ME, Coppola V, Saragovi HU, Randazzo PA, Tessarollo L. A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. The Journal of Cell Biology. 173: 291-9. PMID 16636148 DOI: 10.1083/jcb.200512013  1
2006 Ivanisevic L, Saragovi HU. The Neurotrophins Handbook of Biologically Active Peptides. 1407-1413. DOI: 10.1016/B978-012369442-3/50199-9  1
2005 Saragovi HU. Progression of age-associated cognitive impairment correlates with quantitative and qualitative loss of TrkA receptor protein in nucleus basalis and cortex. Journal of Neurochemistry. 95: 1472-80. PMID 16219032 DOI: 10.1111/j.1471-4159.2005.03479.x  1
2005 Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, Bengio Y, Burgess K, Saragovi HU. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chemistry & Biology. 12: 1015-28. PMID 16183026 DOI: 10.1016/j.chembiol.2005.06.015  1
2005 Thomas MS, Zhang W, Jordan PM, Saragovi HU, Taglialatela G. Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells. Journal of Neuroinflammation. 2: 19. PMID 16144552 DOI: 10.1186/1742-2094-2-19  1
2005 Nedev HN, Klaiman G, LeBlanc A, Saragovi HU. Synthesis and evaluation of novel dipeptidyl benzoyloxymethyl ketones as caspase inhibitors. Biochemical and Biophysical Research Communications. 336: 397-400. PMID 16137654 DOI: 10.1016/j.bbrc.2005.08.098  1
2005 Tyurina YY, Nylander KD, Mirnics ZK, Portugal C, Yan C, Zaccaro C, Saragovi HU, Kagan VE, Schor NF. The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell. 4: 187-96. PMID 16026333 DOI: 10.1111/j.1474-9726.2005.00160.x  1
2005 Mirnics ZK, Yan C, Portugal C, Kim TW, Saragovi HU, Sisodia SS, Mirnics K, Schor NF. P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of Disease. 20: 969-85. PMID 16006137 DOI: 10.1016/j.nbd.2005.06.004  1
2005 Yan C, Mirnics ZK, Portugal CF, Liang Y, Nylander KD, Rudzinski M, Zaccaro C, Saragovi HU, Schor NF. Cholesterol biosynthesis and the pro-apoptotic effects of the p75 nerve growth factor receptor in PC12 pheochromocytoma cells. Brain Research. Molecular Brain Research. 139: 225-34. PMID 15967538 DOI: 10.1016/j.molbrainres.2005.05.025  1
2005 Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. Dna and Cell Biology. 24: 350-8. PMID 15941387 DOI: 10.1089/dna.2005.24.351  1
2005 Li S, Saragovi HU, Nedev H, Zhao C, Racine RJ, Fahnestock M. Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis. Molecular and Cellular Neurosciences. 29: 162-72. PMID 15911341 DOI: 10.1016/j.mcn.2005.02.007  1
2005 Saragovi HU. Introduction: Strategies, molecular targets and animal models useful for developing therapies for Alzheimer's disease Current Medicinal Chemistry - Central Nervous System Agents. 5: 1-3.  1
2005 Rudzinski M, Saragovi HU. Glaucoma: Validated and facile in vivo experimental models of a chronic neurodegenerative disease for drug development Current Medicinal Chemistry - Central Nervous System Agents. 5: 43-49.  1
2004 Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Annals of Neurology. 56: 520-31. PMID 15455399 DOI: 10.1002/ana.20233  1
2004 Bruno MA, Clarke PB, Seltzer A, Quirion R, Burgess K, Cuello AC, Saragovi HU. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 8009-18. PMID 15371501 DOI: 10.1523/JNEUROSCI.1508-04.2004  1
2004 Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Current Cancer Drug Targets. 4: 313-26. PMID 15180497 DOI: 10.2174/1568009043332989  1
2004 Guillemard V, Saragovi HU. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity Oncogene. 23: 3613-3621. PMID 15034547 DOI: 10.1038/sj.onc.1207463  1
2004 Lee HB, Zaccaro MC, Pattarawarapan M, Roy S, Saragovi HU, Burgess K. Syntheses and activities of new C10 beta-turn peptidomimetics. The Journal of Organic Chemistry. 69: 701-13. PMID 14750794 DOI: 10.1021/jo034167x  1
2004 Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. Journal of Neurobiology. 58: 341-54. PMID 14750147 DOI: 10.1002/neu.10293  1
2003 Ivanisevic L, Banerjee K, Saragovi HU. Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene. 22: 5677-85. PMID 12944916 DOI: 10.1038/sj.onc.1206864  1
2003 Pattarawarapan M, Reyes S, Xia Z, Zaccaro MC, Saragovi HU, Burgess K. Selective formation of homo- and heterobivalent peptidomimetics. Journal of Medicinal Chemistry. 46: 3565-7. PMID 12904060 DOI: 10.1021/jm034103e  1
2003 Li S, Uri Saragovi H, Racine RJ, Fahnestock M. A ligand of the p65/p95 receptor suppresses perforant path kindling, kindling-induced mossy fiber sprouting, and hilar area changes in adult rats. Neuroscience. 119: 1147-56. PMID 12831869 DOI: 10.1016/S0306-4522(03)00239-2  1
2003 Taheri M, Saragovi HU, Stanners CP. The adhesion and differentiation-inhibitory activities of the immunoglobulin superfamily member, carcinoembryonic antigen, can be independently blocked. The Journal of Biological Chemistry. 278: 14632-9. PMID 12571231 DOI: 10.1074/jbc.M212500200  1
2002 Saragovi HU, Zaccaro MC. Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites. Current Pharmaceutical Design. 8: 2201-16. PMID 12369863 DOI: 10.2174/1381612023393215  1
2001 Zaccaro MC, Ivanisevic L, Perez P, Meakin SO, Saragovi HU. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. The Journal of Biological Chemistry. 276: 31023-9. PMID 11425862 DOI: 10.1074/jbc.M104630200  1
2001 Guillemard V, Saragovi HU. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Research. 61: 694-9. PMID 11212270  1
2001 Burgess K, Han I, Zhang A, Zheng WH, Shanmugam K, Featherstone MS, Saragovi HU. DiSSiMiL: Diverse Small Size Mini-Libraries applied to simple and rapid epitope mapping of a monoclonal antibody. The Journal of Peptide Research : Official Journal of the American Peptide Society. 57: 68-76. PMID 11168890 DOI: 10.1034/j.1399-3011.2001.00786.x  1
2000 Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, Saragovi HU, Kordower JH. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. The Journal of Comparative Neurology. 427: 19-30. PMID 11042589 DOI: 10.1002/1096-9861(20001106)427:1<19::AID-CNE2>3.0.CO;2-A  1
2000 Beglova N, Maliartchouk S, Ekiel I, Zaccaro MC, Saragovi HU, Gehring K. Design and solution structure of functional peptide mimetics of nerve growth factor. Journal of Medicinal Chemistry. 43: 3530-40. PMID 11000007 DOI: 10.1021/jm990441x  1
2000 la Sala A, Corinti S, Federici M, Saragovi HU, Girolomoni G. Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. Journal of Leukocyte Biology. 68: 104-10. PMID 10914496  1
2000 Maliartchouk S, Debeir T, Beglova N, Cuello AC, Gehring K, Saragovi HU. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. The Journal of Biological Chemistry. 275: 9946-56. PMID 10744669 DOI: 10.1074/jbc.275.14.9946  1
2000 Sendera TJ, Ma SY, Jaffar S, Kozlowski PB, Kordower JH, Mawal Y, Saragovi HU, Mufson EJ. Reduction in TrkA-immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome. Journal of Neurochemistry. 74: 1185-96. PMID 10693951  1
2000 Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends in Pharmacological Sciences. 21: 93-8. PMID 10689362 DOI: 10.1016/S0165-6147(99)01444-3  1
2000 Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello AC, Burgess K, Saragovi HU. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Molecular Pharmacology. 57: 385-91. PMID 10648649  1
2000 Cuello AC, Saragovi HU. To make neurons repel Biofutur. 20-23.  1
1999 Saragovi HU, Rebai N, Di Guglielmo GM, Macleod R, Sheng J, Rubin DH, Greene MI. A G1 cell cycle arrest induced by ligands of the reovirus type 3 receptor is secondary to inactivation of p21ras and mitogen-activated protein kinase. Dna and Cell Biology. 18: 763-70. PMID 10541435 DOI: 10.1089/104454999314908  1
1999 Shanmugam K, Green NC, Rambaldi I, Saragovi HU, Featherstone MS. PBX and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins. Molecular and Cellular Biology. 19: 7577-88. PMID 10523646  1
1999 Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proceedings of the National Academy of Sciences of the United States of America. 96: 4067-72. PMID 10097164 DOI: 10.1073/pnas.96.7.4067  1
1999 Saragovi HU, Burgess K. Small molecule and protein-based neurotrophic ligands: Agonists and antagonists as therapeutic agents Expert Opinion On Therapeutic Patents. 9: 737-751. DOI: 10.1517/13543776.9.6.737  1
1998 Saragovi HU, Zheng W, Maliartchouk S, DiGugliemo GM, Mawal YR, Kamen A, Woo SB, Cuello AC, Debeir T, Neet KE. A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. The Journal of Biological Chemistry. 273: 34933-40. PMID 9857023 DOI: 10.1074/jbc.273.52.34933  1
1998 Saragovi HU, Bhandoola A, Moreau JL, Lavine N, Gagnon M, Lemercier MM, Théze J. Functional and physical association of a cell surface phospholipid and interleukin-2 receptor p55(alpha) subunits. Biochimica Et Biophysica Acta. 1414: 51-64. PMID 9804890 DOI: 10.1016/S0005-2736(98)00152-7  1
1998 Debeir T, Saragovi HU, Cuello AC. TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo. Journal of Physiology, Paris. 92: 205-8. PMID 9789809 DOI: 10.1016/S0928-4257(98)80011-9  1
1998 Beglova N, LeSauteur L, Ekiel I, Saragovi HU, Gehring K. Solution structure and internal motion of a bioactive peptide derived from nerve growth factor. The Journal of Biological Chemistry. 273: 23652-8. PMID 9726969 DOI: 10.1074/jbc.273.37.23652  1
1998 Saragovi HU, Rebai N, Roux E, Gagnon M, Zhang X, Robaire B, Bromberg J, Greene MI. Signal transduction and antiproliferative function of the mammalian receptor for type 3 reovirus. Current Topics in Microbiology and Immunology. 233: 155-66. PMID 9599925  1
1997 Kramer K, Cheung NK, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, LeSauter L, Saragovi HU. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 33: 2098-100. PMID 9516861 DOI: 10.1016/S0959-8049(97)00211-6  1
1997 Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NK. Monoclonal antibody to human Trk-A: diagnostic and therapeutic potential in neuroblastoma. European Journal of Cancer (Oxford, England : 1990). 33: 2090-1. PMID 9516859 DOI: 10.1016/S0959-8049(97)00210-4  1
1997 Maliartchouk S, Saragovi HU. Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 6031-7. PMID 9236214  1
1997 Shanmugam K, Featherstone MS, Saragovi HU. Residues flanking the HOX YPWM motif contribute to cooperative interactions with PBX. The Journal of Biological Chemistry. 272: 19081-7. PMID 9228093 DOI: 10.1074/jbc.272.30.19081  1
1997 Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Experimental Neurology. 146: 91-103. PMID 9225742 DOI: 10.1006/exnr.1997.6504  1
1996 Kramer K, Gerald W, LeSauteur L, Saragovi HU, Cheung NKV. Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma Clinical Cancer Research. 2: 1361-1367. PMID 9816308  1
1996 LeSauteur L, Cheung NK, Lisbona R, Saragovi HU. Small molecule nerve growth factor analogs image receptors in vivo. Nature Biotechnology. 14: 1120-2. PMID 9631063 DOI: 10.1038/nbt0996-1120  0.36
1996 LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 1308-16. PMID 8778282  1
1995 LeSauteur L, Wei L, Gibbs BF, Saragovi HU. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. The Journal of Biological Chemistry. 270: 6564-9. PMID 7896793 DOI: 10.1074/jbc.270.12.6564  1
1995 Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. The Journal of Clinical Investigation. 95: 1814-23. PMID 7706488 DOI: 10.1172/JCI117860  1
1995 Saragovi HU, Bhandoola A, Lemercier MM, Akbar GK, Greene MI. A receptor that subserves reovirus binding can inhibit lymphocyte proliferation triggered by mitogenic signals. Dna and Cell Biology. 14: 653-64. PMID 7646812 DOI: 10.1089/dna.1995.14.653  1
1993 Sauvé GJ, Saragovi HU, Greene MI. Reovirus receptors. Advances in Virus Research. 42: 325-41. PMID 8430522  1
1993 Reed JC, Torigoe T, Turner BC, Merida I, Gaulton G, Saragovi HU, Rapp UR, Taichman R. Protooncogene-encoded protein kinases in interleukin-2 signal transduction. Seminars in Immunology. 5: 327-36. PMID 8260649 DOI: 10.1006/smim.1993.1039  1
1992 Torigoe T, Saragovi HU, Reed JC. Interleukin 2 regulates the activity of the lyn protein-tyrosine kinase in a B-cell line. Proceedings of the National Academy of Sciences of the United States of America. 89: 2674-8. PMID 1557373  1
1992 Reed JC, Tanaka S, Cuddy M, Cho D, Smith J, Kallen R, Saragovi HU, Torigoe T. A strategy for generating monoclonal antibodies against recombinant baculovirus-produced proteins: application to the Bcl-2 oncoprotein. Analytical Biochemistry. 205: 70-6. PMID 1443560 DOI: 10.1016/0003-2697(92)90580-Z  1
1992 Saragovi HU, Greene MI, Chrusciel RA, Kahn M. Loops and secondary structure mimetics: development and applications in basic science and rational drug design. Bio/Technology (Nature Publishing Company). 10: 773-8. PMID 1368266  1
1992 Chen S, Chrusciel RA, Nakanishi H, Raktabutr A, Johnson ME, Sato A, Weiner D, Hoxie J, Saragovi HU, Greene MI. Design and synthesis of a CD4 beta-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 89: 5872-6. PMID 1352879 DOI: 10.1073/pnas.89.13.5872  1
1991 Saragovi HU, Fitzpatrick D, Raktabutr A, Nakanishi H, Kahn M, Greene MI. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science (New York, N.Y.). 253: 792-5. PMID 1876837  1
Show low-probability matches.